Benign Skin Lesions

Meet the patient

A 54-year-old asks you to "just freeze this brown spot" on his back. It has been there for years, but his wife says it has changed colour over three months, and on dermoscopy it is asymmetric, with two colours and an evolving edge. [1]

The trap is already set: he wants the quick destructive treatment, and the lesion is ABCDE-positive. The single decision that matters — and the one the whole topic exists to teach — is biopsy before you burn. [1]

Triage first — the destructive-vs-excise rule

Benign lesions are common; the disaster is destroying a malignancy you never characterised. Your job is not to remove every lesion but to sort them: recognise the benign pattern, reassure, and biopsy the one that does not fit. [1]

The cardinal screen for any pigmented lesion is ABCDE — Asymmetry, Border irregularity, Colour variation, Diameter over 6 mm, and Evolving — plus the ugly duckling sign: the mole that looks different from the patient's other moles is the suspicious one. Any pigmented lesion meeting these criteria, or any rapidly growing or bleeding lesion regardless of colour, needs excisional biopsy with a 2 mm margin rather than destructive treatment. [1]

Dermoscopy is the bedside tool that does the sorting. Adding dermoscopy to naked-eye examination improves sensitivity for melanoma and keratinocyte cancers and cuts unnecessary excisions; the Triage Amalgamated Dermoscopic Algorithm (TADA) teaches the common benign patterns first, then flags everything else for expert review. [2][9]

Classification — by tissue of origin

Each lineage produces a recognisable clinical and dermoscopic pattern, and examiners reward naming the lesion, its lineage and its defining sign in one breath. [1]

[1]

Milia (tiny white epidermal keratin cysts on the eyelids and cheeks), syringoma (flesh-coloured papules from eccrine ducts on the lower eyelids), skin tags (acrochordons — pedunculated fleshy papules in flexures) and acral naevi complete the catalogue. The high-yield point is that each lesion has a single defining clinical sign or dermoscopic feature that, once seen, makes the diagnosis instant. [1]

Epidemiology — the lesion follows its demographic

[1]

Seborrhoeic keratosis is essentially universal in the elderly — prevalence climbs from a few per cent in the third decade to near-total by the eighth. Acquired melanocytic naevi accumulate through childhood, peak at 20–40 years (10–40 moles on average), then regress; a high naevus count (over 50, or any naevus over 5 mm) is the strongest phenotypic risk factor for melanoma. [1]

Pyogenic granuloma is commonest in children, young adults and pregnant women (granuloma gravidarum, often on the gingiva). Dermatofibroma predominates in young-to-middle-aged women, classically on the lower leg, often with a recalled insect bite. [5][6]

Risk factors worth naming: chronic ultraviolet exposure (drives seborrhoeic keratosis and, separately, premalignant actinic keratosis), fair skin, a family history of dysplastic naevi or NF1, immunosuppression, and — for xanthelasma — dyslipidaemia, diabetes, obesity and hypothyroidism. [1]

Pathophysiology — the cell of origin dictates the morphology

Seborrhoeic keratosis is a clonal benign proliferation of basaloid keratinocytes confined to the epidermis, trapping keratin into the pathognomonic comedo-like horn cysts and milia-like cysts. Somatic mutations in FGFR3 and PIK3CA explain its frequency and its benign course. [3]

Melanocytic naevi arise from nevomelanocytes that fail to complete their neural-crest migration and arrest in nests. The naevus matures along a predictable arc: a junctional naevus (flat, pigmented, macular, typical of youth) drops nests into the dermis to become compound (raised, brown), then intradermal (dome, flesh-coloured, face of older adults). This is why a mole becomes less pigmented and more fleshy with age — a benign trajectory the examiner wants articulated. [4]

Pyogenic granuloma is a lobular capillary haemangioma — a benign exuberant proliferation of capillary-sized vessels in lobules within a loose oedematous stroma, eroding through thinned epidermis so it bleeds on the slightest touch. The name is a double misnomer: it is neither pyogenic nor granulomatous. Trauma, pregnancy hormones and retinoids are recognised triggers. [5]

Dermatofibroma (benign fibrous histiocytoma) is a reactive fibrohistiocytic proliferation, most often after minor trauma such as an insect bite; tethering to the overlying epidermis produces the dimple sign. [6] Epidermoid and pilar cysts arise when epidermal or trichilemmal epithelium is implanted or retained in the dermis, forming a wall that continually sheds keratin into an expanding cavity — the cheesy, malodorous material is keratin, not sebum, which is why "sebaceous cyst" is a misnomer. [1]

Clinical presentation — the pathognomonic story

Each benign lesion has a pathognomonic story: site, morphology, feel, and one defining sign. [1]

Seborrhoeic keratosis is a well-defined, oval, "stuck-on" plaque with a waxy or verrucous surface, tan to dark brown or black, that looks as though it has been glued on and could be flicked off. Usually multiple, on the trunk and face, from middle age onward; itch is common. A sudden explosive eruption of many pruritic seborrhoeic keratoses is the Sign of Leser-Trélat — investigate for an internal malignancy, classically gastric adenocarcinoma. [3]

Melanocytic naevi sort by architecture: junctional (flat, evenly pigmented brown macule, regular border, under 6 mm), compound (raised, dome, evenly brown, may show central hair) and intradermal (dome or pedunculated, flesh-coloured, face of older adults). The special types are high-yield: a Spitz naevus is a pink, hairless, firm, rapidly appearing papule in a child; a halo (Sutton) naevus is a pigmented naevus ringed by depigmentation in an adolescent; a blue naevus is a firm blue-black papule of the extremities; a dysplastic (Clark) naevus is larger and irregular. [4]

Pyogenic granuloma is a bright red, glistening, friable papule or nodule that appears and grows over days to weeks at a site of minor trauma and bleeds copiously with the slightest touch. Typical sites are the fingers, lips, oral mucosa (gingiva in pregnancy), face and trunk. [5] Dermatofibroma is a firm, dimpled, brown dermal papule, 3–10 mm, almost always on a lower extremity, tethered to overlying skin but mobile over deeper structures. [6]

Epidermoid cysts are firm, round, mobile, skin-coloured subcutaneous nodules with a visible central punctum on the face, neck, scalp, trunk or scrotum; pilar cysts are firmer scalp nodules (90%) without a punctum, often multiple and inherited. Rupture produces acute inflammation that mimics an abscess. Lipoma is a soft, doughy, lobulated, mobile subcutaneous mass that slips under the examining finger. [1]

Neurofibroma is a soft, flesh-coloured, buttonhole-shaped papule that can be invaginated into the dermis on firm pressure (the buttonhole sign); when multiple, assess for NF1. [8] Xanthelasma is a soft, yellow-orange, slightly raised plaque on the eyelids, most often the medial upper lid, often bilateral and a cutaneous marker of dyslipidaemia. [7]

Differential — the malignancy wearing a benign face

The pitfall is the mimic — a malignancy wearing a benign face. Organise the differential by morphology, and the cardinal rule is: a single atypical feature is enough to biopsy. [1]

The non-malignant mimics matter too: a cherry angioma does not blanch (unlike a spider naevus, which does); a sudden crop of pruritic seborrhoeic keratoses is the Sign of Leser-Trélat, not a benign event. [3][9]

Bedside assessment — the four named signs

Diagnosis is clinical — morphology and distribution — refined by four named manoeuvres and dermoscopy. No blood test diagnoses a benign lesion, though some (xanthelasma, multiple lipomas, NF1) demand a blood test for what they imply systemically. [1]

[1]

Dermoscopy is mandatory for any pigmented lesion. Each benign lesion carries a reproducible pattern: a seborrhoeic keratosis shows comedo-like openings, milia-like cysts and a gyrated "brain-like" surface with no pigment network (separating it from a melanocytic lesion); a dermatofibroma shows a central white scar-like patch with a delicate peripheral pigment network; a pyogenic granuloma shows reddish homogeneous areas with white collarette; a blue naevus shows homogeneous steel-blue pigmentation. [2]

The focused examination includes a total body skin examination (the ugly duckling sign needs the whole mole set for comparison) and, for xanthelasma, a search for other xanthomas and stigmata of dyslipidaemia (corneal arcus, tendon xanthomata). [1]

Investigations — exclude, characterise, implicate

Most benign lesions need no investigation at all. Investigation is necessary in three situations: to exclude malignancy, to characterise a deep lesion, and to assess the systemic implications of a cutaneous marker. [1]

To exclude malignancy, the definitive test is excisional biopsy with a 2 mm margin for any changing, atypical or ugly-duckling-positive pigmented lesion, and shave or punch biopsy with histology for any rapidly growing or bleeding non-pigmented lesion — every pyogenic granuloma is sent for histology to exclude amelanotic melanoma. Destructive treatment without biopsy is never acceptable when there is any diagnostic doubt. [1]

To characterise a deep lesion, a large (over 5 cm), deep, firm, fixed or rapidly growing subcutaneous mass that might be a liposarcoma warrants MRI and needle or incisional biopsy before excision; liposarcoma cannot be reliably distinguished from lipoma clinically. [1]

To assess systemic implications: xanthelasma mandates a fasting lipid panel and a cardiovascular risk assessment; multiple lipomas prompt familial multiple lipomatosis, Dercum disease and Madelung disease; multiple neurofibromas prompt a full NF1 work-up against the revised 2021 criteria, including slit-lamp for Lisch nodules and ophthalmology review. [7][8]

Self-test: which benign lesion always mandates histology even though the diagnosis seems obvious?

Pyogenic granuloma. An amelanotic melanoma can present as an identical pink, friable, rapidly growing, bleeding nodule, and the two cannot be reliably separated clinically. Every pyogenic granuloma removed — shave, curettage or excision — is sent for histopathology, and the feeding vessel at the base is electrocauterised to prevent the roughly 40% recurrence. [5]

Management — the safety step first

Benign lesions are not time-critical in themselves, but two presentations carry urgency. An acutely bleeding pyogenic granuloma is controlled with firm direct pressure for 10 minutes, then definitive ablation of the feeding vessel; an acutely inflamed, infected epidermoid cyst is managed as an abscess (incision and drainage, a swab, oral flucloxacillin 500 mg four times daily for seven days if there is surrounding cellulitis) with definitive excision deferred until the inflammation settles. [5]

The most important "urgent" decision is diagnostic, not therapeutic: a lesion that might be melanoma is biopsied before any destructive treatment — no exceptions. [1]

Management — definitive and stepwise

Leave it if it is benign and asymptomatic; remove it if it is symptomatic, cosmetic or in diagnostic doubt; and never destroy a lesion you have not first characterised. [1]

Seborrhoeic keratosis — reassure and leave; if itchy, catching or cosmetically unacceptable, treat with liquid nitrogen cryotherapy (two freeze-thaw cycles), curettage with electrocautery, shave excision or ablative CO2 laser. Send histology whenever the diagnosis is not certain. [3]

Melanocytic naevus — observe with ABCDE and ugly duckling; advise self-examination and sun protection. Excise only if atypical or changing, with excisional biopsy and a 2 mm margin along relaxed skin tension lines. Never shave or destroy a suspicious pigmented lesion — it compromises staging and may upstage a melanoma. Giant congenital naevi (over 20 cm projected adult diameter) carry significant melanoma risk and warrant specialist surveillance. [4]

Pyogenic granuloma — shave excision of the friable tissue followed by electrocautery of the base (the feeder vessel) is standard and cuts recurrence. Always send histology. Recurrence reaches 40% if the feeder vessel is not ablated; recurrent lesions warrant full surgical excision. In pregnancy, defer to the postpartum period if possible. [5]

Dermatofibroma — leave alone; excise only if symptomatic or in diagnostic doubt. Epidermoid and pilar cyst — complete surgical excision of the wall and the punctum when quiescent; an inflamed cyst is incised and drained first, with definitive excision deferred four to six weeks. Never squeeze a cyst. [6]

Lipoma — observe; excise only if symptomatic, cosmetic, growing or suspicious. A lesion over 5 cm, deep, firm, fixed or rapidly growing is biopsied before excision to exclude liposarcoma. [1]

Xanthelasma — address the dyslipidaemia and cardiovascular risk first (statin therapy per regional guidelines, glycaemic and blood pressure control, smoking cessation), because recurrence is common unless lipids are controlled and the systemic risk outweighs the cosmetic one. Local options include surgical excision (watch for ectropion), CO2 or erbium:YAG laser, and trichloroacetic acid peeling; recurrence reaches 40% regardless of modality. [7]

Specific subtypes and syndromes

The Spitz naevus — a pink, firm, hairless, rapidly growing papule in a child (cheek or leg), histologically spindle and epithelioid melanocytes — is the diagnostic trap, mimicking pyogenic granuloma clinically and melanoma histologically. Spitzoid tumours of uncertain malignant potential (STUMP) are managed jointly with complete excision. [4]

The cyst family: epidermoid (face, neck, scrotum, punctum, keratin), pilar (scalp, no punctum, hereditary), milia (tiny superficial cysts, eyelids and cheeks) and dermoid (congenital, along embryonic fusion lines, lateral eyebrow in a child). [1]

The lipoma syndromes: familial multiple lipomatosis (autosomal dominant, forearms and thighs), Dercum disease (painful lipomas in postmenopausal women) and Madelung disease (symmetric non-encapsulated fat around the neck and upper trunk in middle-aged men, linked to alcohol misuse). A rapidly growing, deep, firm or fixed mass is liposarcoma until proven otherwise. [1]

Neurofibroma and NF1: multiple neurofibromas mandate assessment against the revised 2021 criteria — two or more of six or more café-au-lait macules, skinfold freckling, two or more neurofibromas or one plexiform, optic pathway glioma, two or more Lisch nodules, a characteristic bony lesion, a pathogenic NF1 variant, or an affected first-degree relative. [8]

Complications — the five avoidable errors

The complications are mostly iatrogenic and avoidable. [1]

[1]

Procedure-related complications: cryotherapy causes hypopigmentation (a major concern in dark skin); curettage without histology forfeits diagnosis; lipoma excision risks haematoma and nerve injury; xanthelasma excision risks ectropion if too much eyelid skin is removed. [1]

Prognosis and disposition

For a truly benign lesion the prognosis is excellent — the lesion is harmless, and treatment, when needed, is cosmetic and curative. Three nuances matter: dysplastic naevi are markers (not premalignant lesions) of melanoma risk and enter a surveillance programme; giant congenital naevi carry a real melanoma and neurocutaneous-melanosis risk; and xanthelasma is a prognostic flag for atherosclerotic disease, independent of lipid levels. [7]

Most benign lesions are managed in primary care or dermatology outpatients; cyst or lipoma excision is a day-case. Suspected NF1, dysplastic naevus syndrome, giant congenital naevi, or suspected liposarcoma or MPNST are referred to specialist services. The safety-net for every patient: return if the lesion changes in size, shape, colour or sensation, or bleeds. [1]

Special populations

[1]

The anticoagulated patient bleeds more with any excision (plan cautery and pressure dressings; do not stop anticoagulants for minor skin surgery); the patient with multiple neurofibromas is assessed for NF1 against the 2021 criteria. [8]

Evidence and regional differences

The evidence base for benign lesion recognition is anchored on dermoscopy: the 2018 Cochrane review by Dinnes showed dermoscopy improves sensitivity for melanoma and keratinocyte cancers, and the 2019 Seiverling TADA study showed that teaching the benign patterns first improves triage. [2][9]

[1]

Where the evidence is weak: the optimal management of a Spitz naevus in an adult remains debated (excise versus observe), reflecting the difficulty of separating a benign Spitz naevus from a spitzoid melanoma; and recurrence after xanthelasma treatment is high (up to 40%) with every modality, so systemic lipid management is the more important intervention. [4][7]

Exam pearls

[1]

Exam application bank (NEET-PG and INICET)

One-line answer

Benign skin lesions are the commonest tumours in medicine; the skill is triage — tell benign from malignant with dermoscopy and ABCDE, biopsy any changing or atypical lesion before destructive treatment, and recognise the catalogue (seborrhoeic keratosis, melanocytic naevi, pyogenic granuloma, dermatofibroma, epidermoid and pilar cysts, lipoma, xanthelasma). Named signs: dimple (dermatofibroma), buttonhole (neurofibroma), punctum (epidermoid cyst), ugly duckling (the suspicious mole). [1]

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and first treatment step with dose and route if drug therapy is standard. [1] Stem 2 — Unstable or complicated. List red flags that force immediate resuscitation, theatre, ICU, antidote or reperfusion — and what you do in the first 15 minutes. [1] Stem 3 — Atypical group. Elderly, pregnancy, child or immunocompromised: how presentation and thresholds change. [1] Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each. [1] Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU, ICU or theatre, and what follow-up is mandatory. [1]

Rapid viva checklist

1. Definition and classification
2. Pathophysiology chain
3. Bedside signs and criteria
4. Score with exact components
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline or trial name if classic
10. Three exam traps

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Benign Skin Lesions. [1]

Ward-round test — three stems, thirty seconds each

Stem 1 — the changing mole that wants freezing (answer)

The 54-year-old with the "freeze this brown spot" request. His lesion is ABCDE-positive on dermoscopy. What is the error, and what do you do? Model: The error is destructive treatment before biopsy — cryotherapy of an unrecognised melanoma is the preventable disaster. This lesion is Asymmetric, Border-irregular, Colour-variable, over 6 mm Diameter and Evolving. The correct action is an excisional biopsy with a 2 mm clinical margin, orienting the ellipse along relaxed skin tension lines and marking the specimen — never shave, freeze or cauterise a suspicious pigmented lesion, because it compromises histological staging and may upstage a melanoma. Total-body skin examination for the ugly duckling sign, then surveillance. [1]

Stem 2 — the bleeding nodule on the finger (answer)

A 23-year-old carpenter has a red, friable nodule on his index finger, 8 mm and glistening, appearing two weeks after a minor injury and bleeding whenever he knocks it. What is it, and what is the safety step? Model: This is a pyogenic granuloma (lobular capillary haemangioma) — a rapidly growing, friable, bleeding papule at a trauma site in a young adult; the name is a double misnomer (neither pyogenic nor granulomatous). Definitive treatment is shave excision followed by electrocautery of the base (the feeder vessel, to prevent the roughly 40% recurrence). The safety step is histopathology on every pyogenic granuloma removed, because an amelanotic melanoma can present as an identical pink, friable, bleeding nodule and cannot be separated clinically. [5]

Stem 3 — the soft mass on the thigh (answer)

A 62-year-old has a 7 cm, deep, firm, slowly growing mass on the right thigh that "feels like a lipoma". It is fixed to deep structures. What changes your plan? Model: A large (over 5 cm), deep, firm, fixed or growing subcutaneous mass is liposarcoma until proven otherwise — liposarcoma cannot be reliably distinguished from lipoma clinically. Do not shell it out blind. The plan changes to MRI and a needle or incisional biopsy before excision, with surgical planning guided by the histology and a multidisciplinary team. [1]

The mantra: recognise the benign pattern, reassure the patient — and never destroy a lesion you have not first characterised. [1][9]

References

1. [1]Brodsky J. Management of benign skin lesions commonly affecting the face: actinic keratosis, seborrheic keratosis, and rosacea Curr Opin Otolaryngol Head Neck Surg, 2009.PMID 19465852
2. [2]Dinnes J, Deeks JJ, Chuchu N, et al. Visual inspection and dermoscopy, alone or in combination, for diagnosing keratinocyte skin cancers in adults Cochrane Database Syst Rev, 2018.PMID 30521688
3. [3]Barthelmann S, Butsch F, Lang BM, et al. Seborrheic keratosis J Dtsch Dermatol Ges, 2023.PMID 36892019
4. [4]Jahnke MN, O'Haver J, Gupta D, et al. Care of Congenital Melanocytic Nevi in Newborns and Infants: Review and Management Recommendations Pediatrics, 2021.PMID 34845496
5. [5]Komakech D, Ssenkumba B. Pyogenic Granuloma N Engl J Med, 2022.PMID 36416770
6. [6]Bandyopadhyay MR, Besra M, Dutta S, et al. Dermatofibroma: Atypical Presentations Indian J Dermatol, 2016.PMID 26955137
7. [7]Laftah Z, Al-Niaimi F. Xanthelasma: An Update on Treatment Modalities J Cutan Aesthet Surg, 2018.PMID 29731585
8. [8]Legius E, Messiaen L, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation Genet Med, 2021.PMID 34012067
9. [9]Seiverling EV, Ahrns HT, Greene A, et al. Teaching Benign Skin Lesions as a Strategy to Improve the Triage Amalgamated Dermoscopic Algorithm (TADA) J Am Board Fam Med, 2019.PMID 30610147